RNA transfection

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable

Retrieved on: 
Monday, January 9, 2023
IND, Muscular Dystrophy Association, Therapy, MDA, RNA transfection, Duchenne muscular dystrophy, EEV, Entrada, Conference, DMD, Exon, Patient, Episcopal conference, Investigational New Drug, PMO, Pharmaceutical industry, Duchenne

The Company plans to submit an Investigational New Drug (IND) application in the second half of 2024.

Key Points: 
  • The Company plans to submit an Investigational New Drug (IND) application in the second half of 2024.
  • “There is a profound unmet need for people living with Duchenne and the more than 1,300 people in the US and Europe who are exon 45 skipping amenable,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Entrada plans to present additional data in support of ENTR-601-45 at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in March 2023.
  • ENTR-601-45 is designed to address the underlying cause of Duchenne muscular dystrophy due to mutated or missing exons in the DMD gene.

ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Health, Genetics, Science, Research, CRISPR, Cell, Bayer, Therapy, RNA transfection, Recode, SORT, DNA, Gene editing, Patient, Liver, MBA, Vaccine, Pharmaceutical industry, LNP

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG.

Key Points: 
  • ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG.
  • This strategic collaboration is focused on the discovery of precision genetic medicines through the development of a novel platform for full gene insertion by single vector delivery of gene editing and DNA cargoes.
  • The collaboration could extend the reach of gene editing for liver and lung disease targets.
  • Proceeds from the financing are being used to advance the development of ReCode’s platform and pipeline to selectively deliver genetic medicines to targeted organ and cell types in a predictable and programmable fashion.

CF Foundation Invests Up to $15M in ReCode Therapeutics for Development of mRNA Therapy

Retrieved on: 
Tuesday, January 10, 2023
Biotechnology, Health, Other Health, Pharmaceutical, Other Philanthropy, Philanthropy, Other Science, Research, General Health, Fund Raising, Genetics, Foundation, Science, Clinical Trials, Cell, Cystic fibrosis transmembrane conductance regulator, Valencia CF Foundation, Cystic fibrosis, COVID-19, RNA transfection, Recode, CFTR, MD, Mutation, Cystic Fibrosis Foundation, Vaccine, LNP, Conference, RNA, CF, Research, Pharmaceutical industry

The CF Foundation joins other institutional and strategic investors who participated in ReCode’s Series B financing, totaling $210 million.

Key Points: 
  • The CF Foundation joins other institutional and strategic investors who participated in ReCode’s Series B financing, totaling $210 million.
  • ReCode is developing an inhaled mRNA therapy, designed to provide a correct copy of the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA to lung cells to make a functional CFTR protein .
  • These LNPs may allow genetic therapies to enter lung cells more easily and importantly may allow safe redosing of the CFTR mRNA.
  • In lab tests, ReCode demonstrated their mRNA therapy can be delivered in an aerosol form to human lung cells.

Fosun International Receives Four Awards from Corporate Governance Asia

Retrieved on: 
Wednesday, January 11, 2023
Government, Education, HKEX, ESG, RNA transfection, Vaccination, COVID-19, Virus, Best, Fosun Pharma, Growth, Patient, JD, Qiyu Zhou, Malaria, Asian Excellence Awards, Social responsibility, ABC Family Worldwide, Omicron, Health, Culture, BioNTech, Taiwan Excellence Awards, The Bund Finance Center, Human, COVID, Management, Pharmaceutical industry, Fosun International, Azvudine

HONG KONG, Jan. 11, 2023 /PRNewswire/ -- On 11 January 2023, the Corporate Governance Asia magazine presented the 12th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International Limited ("Fosun International" or "Fosun" or the "Group") (HKEX: 00656) were both honoured Asia's Best CEO. In addition, Fosun International was awarded Asia's Best CSR and Best Corporate Communications awards.

Key Points: 
  • Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International Limited ("Fosun International" or "Fosun" or the "Group") (HKEX: 00656) were both honoured Asia's Best CEO.
  • Corporate Governance Asia is one of the most authoritative corporate governance journals in the Asian-Pacific region.
  • Chen Qiyu, Executive Director and Co-CEO of Fosun International, said, "We are very honoured to receive several awards from Corporate Governance Asia, including Asia's Best CEO and Asia's Best CSR.
  • According to Corporate Governance Asia, in response to the pandemic, Fosun took the initiative to undertake corporate social responsibility.

AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

Retrieved on: 
Tuesday, January 10, 2023
Research, Anima, AbbVie, Immunology, Lightning, NYSE, RNA transfection, Vaccine, Pharmaceutical industry, Oncology

NORTH CHICAGO, Ill. and BERNARDSVILLE, N.J., Jan. 10, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.

Key Points: 
  • NORTH CHICAGO, Ill. and BERNARDSVILLE, N.J., Jan. 10, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology.
  • Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.
  • "Modulating mRNA biology with small molecules is a new approach and has the potential to address 'undruggable' targets with implications across multiple therapy areas."
  • AbbVie has an option to expand the collaboration with up to three additional targets under the same terms as the initial collaboration, which may increase the potential value of the collaboration.

KromaTiD Announces Launch of Plasmid DNA Manufacturing Service

Retrieved on: 
Monday, January 9, 2023
Research, III, Transfection, DNA, Regenerative medicine, Vaccine, RUO, RNA transfection, CGMP, II

LONGMONT, Colo., Jan. 9, 2023 /PRNewswire/ -- KromaTiD, a supplier of unique next-level molecular tools and services, announced today that it has expanded its offerings to include plasmid DNA manufacturing.

Key Points: 
  • LONGMONT, Colo., Jan. 9, 2023 /PRNewswire/ -- KromaTiD, a supplier of unique next-level molecular tools and services, announced today that it has expanded its offerings to include plasmid DNA manufacturing.
  • Plasmid manufacturing is integral for the development of novel vaccines as well as cell and gene therapeutics but the high demand for this service has resulted in long wait times and considerable expense for customers.
  • KromaTiD has recently expanded its manufacturing facilitates by adding a set of state-of-the-art plasmid production suites, dedicated to supporting regenerative medicine customers from preclinical research through clinical trials and commercial production.
  • "We are excited to be launching plasmid manufacturing as a new service offering here at KromaTiD," says Chief Technology Officer Dr. Christopher Tompkins.

Alexandria Venture Investments Ranked as #1 Most Active Corporate Investor in Biopharma for Sixth Consecutive Year

Retrieved on: 
Monday, January 9, 2023
Annual report, Cancer, Shoulder, RNA interference, Agtech, Alexandria Real Estate Equities, Silicon Valley Bank, Head, Silicon, RNA transfection, Research, AAA, COVID-19, Disease, Patient, NYSE, Medicine, Biology, Health, Investment, Therapy, Nobel Prize, History, Vaccine, RNA, REIT, Medical device, Pharmaceutical industry, Alnylam Pharmaceuticals

PASADENA, Calif., Jan. 9, 2023 /PRNewswire/ -- Alexandria Venture Investments, the strategic venture capital platform of Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science, agtech and technology campuses in AAA innovation cluster locations with over 1,000 tenants, today announced that it was recognized by Silicon Valley Bank in its "Healthcare Investments and Exits: Annual Report 2022" as the #1 most active corporate investor in biopharma by new deal volume (2021–2022) for the sixth consecutive year. This important distinction demonstrates Alexandria's position as a key leader and trusted partner within the life science industry. Since the platform's launch in 1996, Alexandria Venture Investments has actively invested in world-leading life science companies as well as promising agrifoodtech and climate innovation companies that are advancing new, transformative therapeutic modalities and innovative life science platforms to meaningfully improve human health. Alexandria's strategic venture activity, a bedrock of its mission-driven business, continues to provide deep insights into key macro life science industry and innovation trends; build and nurture strong relationships with serial entrepreneurs, world-renowned academic institutions and venture investors; and further enhance the REIT industry-leading tenant roster it has diligently cultivated over the years.

Key Points: 
  • This important distinction demonstrates Alexandria's position as a key leader and trusted partner within the life science industry.
  • Individuals with type 1 diabetes, for example, make an estimated 180 health-related decisions daily — that's one decision every five minutes.
  • Recognizing the immense potential of Alnylam's RNAi technology platform, Alexandria invested in its Series A financing in 2002.
  • The most impactful innovation of the 21st century is at the intersection of biology and technology, for which the future prospects are enormous.

Foundational RNA and cLNP expert Antonin (Tony) de Fougerolles joins Etherna as independent board member

Retrieved on: 
Monday, January 9, 2023
LNP, CSO, Partnership, RNA interference, RNA transfection, Therapy, COVID-19, Series, Alnylam Pharmaceuticals, Research, Tissue, Growth, CGMP, Harvard University, Doctor of Philosophy, RNA, Vaccine, Immunology, Sanofi, Moderna

NIEL, Belgium, Jan. 9, 2023 /PRNewswire/ -- Etherna ("the Company"), a leading mRNA technologies company, announced today that Antonin (Tony) de Fougerolles has joined its board of directors as an independent member.

Key Points: 
  • NIEL, Belgium, Jan. 9, 2023 /PRNewswire/ -- Etherna ("the Company"), a leading mRNA technologies company, announced today that Antonin (Tony) de Fougerolles has joined its board of directors as an independent member.
  • This follows the Company's recent Series B2 financing round to expand investment in its integrated mRNA technology platform and further pursue its new partnership-driven business strategy.
  • "Tony is exceptionally qualified to help ensure Etherna's future corporate growth," added Russell Greig, PhD, Chair of Etherna's board of directors.
  • "I am thrilled to be joining Etherna's board and contributing to its future growth," commented Tony de Fougerolles.

EQS-News: Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Retrieved on: 
Sunday, January 22, 2023
Cancer, RNA transfection, Sherbrooke, Biomarker, Colorectal cancer, Gene expression, Patient, CRC, Conditional sentence, Medical imaging

Currently, Mainz is commercializing ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) across Europe and in select international territories.

Key Points: 
  • Currently, Mainz is commercializing ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) across Europe and in select international territories.
  • In the institution’s pioneering work, researchers tested a battery of novel transcriptional biomarkers using colon cancer samples and precancerous lesions.
  • The five mRNA targets chosen by Mainz Biomed provided the greatest sensitivity and specificity of detection (Herring et al.
  • Mainz expects to complete enrollment for the eAArly Detect in Q1 2023 and targets reporting topline results in 1H 2023.

EQS-News: Defence Therapeutics Inc.: mRNA WITH DEFENCE’S ACCUMTM PROGRAM HAS BEEN INITIATED

Retrieved on: 
Sunday, January 22, 2023
Quality control, Protein, RNA transfection, Therapy, Quality control in tissue engineering, Cytoplasm, USD, Animal, Infection, Egg cell, Defense, Vaccine, Neoplasm

Vancouver, BC, Canada, January 10th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program.

Key Points: 
  • Vancouver, BC, Canada, January 10th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program.
  • The mRNA vaccination approach offers tremendous advantages over the use of peptide- or protein-based vaccines.
  • Defence is working with a private European company to synthesize mRNA vaccine coupled with its AccumTM.
  • Defence is advancing on the second step, which consists of coupling AccumTM variants to amino-modified mRNA as well as testing and analyzing: i) the effect of AccumTM and linkers on mRNA stability, ii) the linker coupling onto amino-modified mRNA, iii) the AccumTM coupling onto linker-amino modified mRNA, and finally iv) the purification and analysis of the AccumTM-linker-amino-modified mRNA.